Sublocade just received an FDA label update, making it easier and faster for patients to start treatment while offering more flexibility in administration.
Rapid Induction: No More 7-Day Wait
One of the biggest changes is the approval of a rapid induction pathway. Previously, patients needed a full seven days of buprenorphine treatment before transitioning to Sublocade. Now, they can start Sublocade just one hour after a single 4mg test dose of transmucosal buprenorphine.
This update means:
- Faster time to reach therapeutic levels
- Reduced risk of relapse during the induction period
- More streamlined access to long-acting treatment
An open-label study confirmed that rapid induction was non-inferior to the standard seven-day induction period, reinforcing its effectiveness. The study included patients with moderate to severe opioid use disorder, categorized as high-risk users (5+ days of opioid use per week, equivalent to at least 500mg IV heroin).
New Injection Site Options for Greater Comfort
Sublocade remains a subcutaneous injection, but previously, administration was limited to the abdomen. The new label expands approved injection sites to include the thigh, buttock, and back of the upper arm.
This added flexibility:
- Improves patient comfort
- Provides more options based on individual needs
- Makes it easier for providers to administer
Why This Matters
These changes mark a significant step forward in improving access and adherence to long-acting buprenorphine treatment. Faster initiation means fewer barriers, and additional injection sites offer a more patient-centered approach.
For providers treating opioid use disorder, this update means more streamlined care and better outcomes for patients ready to take the next step toward recovery.
